GLP1R and cancer: The incidence rate in the dual metformin and GLP‐1 RA treatment arm for all obesity‐related cancers was 7.5 per 1000 person‐years (vs. 10.1 in the DPP4i arm), and 6.6 (vs. 8.9 in the DPP4i arm) for traditional obesity‐related cancers.